Think ISIP has one more press release to let here spread her wings:
DESCRIPTION PRESS
RELEASE DATE
» Antisense Drug Causes Reduction of C-Raf-1 RNA Levels in Cancer Patients January 12, 2000
» Isis Forms Collaboration with Elan to Develop Antisense Drug for Hepatitis C January 6, 2000
» Isis Announces Disappointing Results from ISIS 2302 Clinical Trial in Crohn's Disease December 15, 1999
» Isis Begins Phase IIa Study of ISIS 2302 for Psoriasis December 9, 1999
» Isis Begins Phase IIa Study of ISIS 2302 for Ulcerative Colitis December 7, 1999
» Isis Announces Financing Facility Commitment up to $120 Million November 22, 1999
» Isis to Proceed with Development of ISIS 3521 and ISIS 5132 as Novartis Concludes Participation November 22, 1999
» Isis Pharmaceuticals Announces Plans to Initiate Phase III Trials of ISIS 3521 November 22, 1999
» Isis Announces Allowance of 450th Patent November 16, 1999
» Isis Presents Data from Phase II Trial of ISIS 2302 in Rheumatoid Arthritis November 15, 1999
» Isis Demonstrates "Switching" of Key Gene Stimulates Effects of Chemotherapeutic Agents November 8, 1999
» Isis Pharmaceuticals Reports Third Quarter 1999 Results October 28, 1999
» Isis and Rhône-Poulenc Rorer Establish Antisense Target Validation Collaboration September 29, 1999
» Isis Pharmaceuticals and Abbott Laboratories Establish Manufacturing Collaboration for Antisense Drugs September 13, 1999
» Ibis Therapeutics, A Division of Isis Pharmaceuticals, Creates New Method to Discover RNA-Binding Drugs September 8, 1999
» Isis in Late Stage Negotiations to Commercialize ISIS 2302 September 2, 1999
» Isis Reacquires Full Rights to ISIS 2302 September 2, 1999
» European Approval of VitraveneTM Triggers $2.5 MM Milestone for Isis August 04, 1999
» Isis Pharmaceuticals Reports Second Quarter 1999 Results July 29, 1999
» Isis Presents Safety and Preliminary Activity Data on Three Antisense Cancer Drugs at ASCO May 18, 1999
» Isis Begins Phase II Testing of Third Anticancer Drug, ISIS 2503 May 10, 1999
» Isis Pharmaceuticals Reports First Quarter 1999 Results April 28, 1999
» Isis and CIBA Vision Announce European CPMP Recommends Approval of VitraveneÔ
for Pateints with Both Newly Diagnosed and Advanced CMV Retinitis April 28, 1999
» Isis and Elan Form Partnership to Develop Oral Antisense Drugs;
TNF-alpha Inhibitor is First Drug Candidate April 12, 1999
» Ibis Therapeutics, A Division of Isis Pharmaceuticals, Receives $6.6 Million
Defense Department Grant To Discover Biological Warfare Drug Countermeasures March 4, 1999
» Isis Reports Year End and Fourth Quarter Results for 1998 February 17, 1999
» Debby Jo Blank Joins Isis Pharmaceuticals as Executive Vice President February 17, 1999
» Isis Announces Organizational Changes February 1, 1999
» Isis and Abbott Establish Target Validation Collaboration January 12, 1999
» Isis and Zeneca Establish Antisense Drug Discovery
Collaboration to Develop Cancer Therapeutics December 21, 1998
» Isis Acquires Antisense Patent and Technology Estate from Gilead Sciences December 18, 1998
» Isis Wins Industry Week Magazine's Technology and Innovation Award December 17, 1998
» Isis Pharmaceuticals' CEO To Be Honored By Crohn's and Colitis Foundation of America December 10, 1998
» Isis Sublicences PNA Technology Patent to Pantheco A/S To Develop Anti-Infective Agents November 16, 1998
» Isis Pharmaceuticals Reports Third Quarter 1998 Results November 03, 1998
» Isis Achieves $7.5 Million Milestone for FDA Approval of Antisense CMV Retinitis Drug
isip.com |
